Biotech developing therapeutics for various conditions including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly. They have just listed on the Frankfurt Stock Exchange. The share price has taken a hit recently as they have raised capital at 10c and currently have an open SPP at the same price which is due to close late this week. Prior to the capital raising, the SP was in a nice uptrend with recent catalysts being orphan drug designation. I'm going with the CR theory that shares around the issue price are a good entry price. Today, the share price ducked under 10c. Once the SPP is out of the way, I'm expecting the uptrend to continue. Plus they have a number of fronts on which they could release news.
